The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study Evaluation Using Ultrasmall Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging in Carotid Disease by Tang, Tjun Y. et al.
A
t
c
t
F
d
C
d
S
L
Journal of the American College of Cardiology Vol. 53, No. 22, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PThe ATHEROMA (Atorvastatin Therapy:
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Oxide-Enhanced Magnetic Resonance Imaging in Carotid Disease
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Martin J. Graves, MSC,* Andrew J. Patterson, PHD,* Jean-Marie U-King-Im, PHD,* Zhi Y. Li, PHD,*
Stewart R. Walsh, MSC,† Andrew P. Brown, BSC,¶ Peter J. Kirkpatrick, FMEDSCI,‡
Elizabeth A. Warburton, DM,§ Paul D. Hayes, MD,† Kevin Varty, MD,† Jonathan R. Boyle, MD,†
Michael E. Gaunt, MD,† Andrew Zalewski, PHD,# Jonathan H. Gillard, MD*
Cambridge, Harlow, and London, United Kingdom; and East Hanover, New Jersey
Objectives The aim of this study was to evaluate the effects of low-dose (10 mg) and high-dose (80 mg) atorvastatin on
carotid plaque inflammation as determined by ultrasmall superparamagnetic iron oxide (USPIO)-enhanced ca-
rotid magnetic resonance imaging (MRI). The hypothesis was that treatment with 80 mg atorvastatin would
demonstrate quantifiable changes in USPIO-enhanced MRI-defined inflammation within the first 3 months of
therapy.
Background Preliminary studies indicate that USPIO-enhanced MRI can identify macrophage infiltration in human carotid
atheroma in vivo and hence may be a surrogate marker of plaque inflammation.
Methods Forty-seven patients with carotid stenosis 40% on duplex ultrasonography and who demonstrated intraplaque
accumulation of USPIO on MRI at baseline were randomly assigned in a balanced, double-blind manner to either
10 or 80 mg atorvastatin daily for 12 weeks. Baseline statin therapy was equivalent to 10 mg of atorvastatin or
less. The primary end point was change from baseline in signal intensity (SI) on USPIO-enhanced MRI in carotid
plaque at 6 and 12 weeks.
Results Twenty patients completed 12 weeks of treatment in each group. A significant reduction from baseline in USPIO-
defined inflammation was observed in the 80-mg group at both 6 weeks (SI 0.13; p  0.0003) and at 12
weeks (SI 0.20; p  0.0001). No difference was observed with the low-dose regimen. The 80-mg atorvastatin
dose significantly reduced total cholesterol by 15% (p  0.0003) and low-density lipoprotein cholesterol by 29%
(p  0.0001) at 12 weeks.
Conclusions Aggressive lipid-lowering therapy over a 3-month period is associated with significant reduction in USPIO-defined
inflammation. USPIO-enhanced MRI methodology may be a useful imaging biomarker for the screening and as-
sessment of therapeutic response to “anti-inflammatory” interventions in patients with atherosclerotic lesions.
(Effects of Atorvastatin on Macrophage Activity and Plaque Inflammation Using Magnetic Resonance Imaging
[ATHEROMA]; NCT00368589) (J Am Coll Cardiol 2009;53:2039–50) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.018r
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ctherothrombosis is a major cause of morbidity and mor-
ality in the Western world and is now widely accepted as a
hronic systemic vascular inflammatory disorder. Inflamma-
ion is a recognized risk factor for the vulnerable atheroscle-
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estabilization. The macrophage is one of the key cellular
ediators of this process (1), and histological studies have
hown that the degree of macrophage infiltration increases
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USPIO-Enhanced MRI Evaluation of Carotid Disease June 2, 2009:2039–50the risk for plaque rupture and
subsequent thromboembolism
(2). Detection of macrophage ac-
tivity, and hence inflammation
within atheroma, could poten-
tially distinguish between vulner-
able and more stable states and
remains one of the key goals of
atheroma imaging.
See page 2053
It has recently been possible to
identify carotid plaque inflam-
mation noninvasively with ul-
trasmall superparamagnetic iron
oxide (USPIO)-enhanced mag-
netic resonance imaging (MRI)
in both animal (3) and in vivo
human studies (4). The concept
that the USPIO contrast me-
dium Sinerem (Guerbet, Roissy,
France) may be useful in the
assessment of inflammatory ac-
ivity in atherosclerotic plaque is strongly supported by the
ndothelial dysfunction theory (5). Dysfunctional endothe-
ium initiates and sustains an inflammatory reaction within
he arterial wall and allows the accumulation of plasma
omponents, such as low-density lipoproteins (LDLs), into
he subendothelial space. Oxidized LDL particles are then
hagocytosed by macrophages, ultimately forming foam
ells. The USPIO particles, of a diameter similar to that of
DL (15 to 25 nm), enter atherosclerotic plaques with an
ncreased endothelial permeability and accumulate in ath-
roma with high macrophage content. This has been shown
y experimental investigations in an atherosclerotic animal
odel (6) using hyperlipidemic rabbits. Histology and
mmunohistochemistry colocalized USPIO to activated
acrophages in the plaque. These changes were not ob-
erved in animals that did not receive USPIO. It was
oncluded that USPIO was phagocytosed by macrophages
n atherosclerotic plaques in a quantity sufficient to cause
usceptibility artifact detectable by MRI.
Since the first statin was approved by the Food and Drug
dministration (FDA) in 1987, these lipid-lowering agents
ave quickly become the gold standard for treatment of
ypercholesterolemia and the cornerstone of therapy for
rimary and secondary prevention of atherosclerotic disease
7). Statins exert their benefits primarily by inhibiting de
ovo cholesterol synthesis and increasing the expression of
ow-density lipoprotein cholesterol (LDL-C) receptors,
hich result in significant reductions of total cholesterol and
DL-C plasma levels. Furthermore, a recent meta-analysis
emonstrated a dose-dependent relationship between statin
Abbreviations
and Acronyms
ES  emboli signal
HDL-C  high-density
lipoprotein cholesterol
LDL  low-density
lipoprotein
LDL-C  low-density
lipoprotein cholesterol
Lp-PLA2  lipoprotein-
associated phospholipase A2
MRI  magnetic resonance
imaging
ROI  region of interest
SI  ultrasmall
superparamagnetic iron
oxide-enhanced magnetic
resonance imaging signal
change
TCD  transcranial Doppler
USPIO  ultrasmall
superparamagnetic iron
oxideherapy and cardiovascular outcome (8), and high-dose ptatin therapy may even decrease the size of atheromatous
laques over time (9). It remains controversial whether
DL-C lowering is the only mechanism underlying the
linical benefit of statins, and it has been postulated that
tatins may also exert their positive clinical effect by LDL-C
ndependent or pleiotropic mechanisms (10,11). One of
hese is attenuation of inflammation, because statins have
een shown to decrease systemic inflammatory markers
12,13). To date, the only noninvasive evidence that statins
educe plaque inflammation in clinical practice has been
ith 18fluorodeoxyglucose positron emission tomography,
ut the associated radiation exposure limits the number of
ositron emission tomography studies that patients can
ndergo, reducing its potential contribution in assessing
herapeutic interventions.
The aim of this study was to evaluate the effects of
ow-dose (10 mg) and high-dose (80 mg) atorvastatin
Lipitor, Pfizer, New York, New York) on macrophage
ctivity and carotid plaque inflammation as determined by
SPIO-enhanced carotid MRI. The hypothesis was that 12
eeks of treatment with atorvastatin would reduce USPIO-
nhanced MRI signal loss (marker of plaque inflammation)
s compared with baseline and that the reduction in signal
oss would be greater in the high-dose group.
ethods
tudy design. THE ATHEROMA (ATORVASTATIN THERAPY: EF-
ECTS ON REDUCTION OF MACROPHAGE ACTIVITY) STUDY. The
valuation using USPIO-enhanced high-resolution MRI in
arotid disease was done as a prospective, randomized, single-
enter, double-blind clinical trial (ISRCTN64894118) (14).
he Institutional Review Board at the study center approved
he protocol, and all participating patients provided written
nformed consent.
Forty-seven subjects were randomly assigned to a high-
r low-dose statin group. The high-dose statin group
eceived 80 mg atorvastatin once daily, and the low-dose
roup received 10 mg atorvastatin once daily for 12 weeks.
he USPIO-enhanced MRI was performed at baseline (i.e.,
efore randomization) and at 6 and 12 weeks. Blood
amples including fasting lipid profile, creatine kinase, liver
unction tests, and serum creatinine levels were obtained at
ach pre-USPIO infusion visit to ensure patient safety.
lood samples for atorvastatin pharmacokinetics and car-
iovascular biomarkers, including highly specific C-reactive
rotein, myeloperoxidase, and lipoprotein-associated phos-
holipase A2 (Lp-PLA2) activity were also collected at
hese visits and were outsourced for independent analysis
Quest Diagnostics, London, United Kingdom). Transcra-
ial Doppler monitoring of the middle cerebral artery was
erformed to measure thromboembolic signals at baseline
nd at 6 and 12 weeks.
Patients were eligible if they had clinically documented
therosclerotic carotid disease and had demonstrated the
resence of inflammation within their carotid lesions on
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June 2, 2009:2039–50 USPIO-Enhanced MRI Evaluation of Carotid DiseaseSPIO-enhanced MRI regardless of symptomatic status
nd met the inclusion criteria and exclusion criteria. The
atients were randomly allocated after the initial carotid
ltrasound had shown at least 40% stenosis and the MRI
emonstrated signal loss on USPIO-enhanced MRI con-
istent with inflamed lesions. Inclusion criteria were as
ollows: 1) male or female 18 to 80 years of age at baseline;
emale subjects had to be of nonchildbearing potential
post-menopausal women who have been amenorrheic 1
ear or pre-menopausal women with a documented hyster-
ctomy or bilateral oophorectomy); 2) positive USPIO-
nhanced MRI of carotid plaque confirmed by an attending
euroradiologist (J.H.G.); this was defined as a signal
ecrease of 10% in 2 or more quadrants between pre- and
ost-USPIO MRI studies (see Image Analysis section); and
) must either have been statin naïve or have been on a
table dose of a statin for 4 weeks before screening, with
o evidence of statin intolerance; permitted statins and total
aily dose were as follows: atorvastatin10 mg, simvastatin
40 mg, pravastatin 40 mg, fluvastatin 80 mg, and
osuvastatin 10 mg.
A subject was not eligible for inclusion in this study if any
f the following criteria applied: 1) required continued use
f nonstatin lipid-modifying therapies (e.g., fibric acid
erivatives, niacin, resins, ezetimibe, fish-oil supplement) or
herapy with any other lipid-regulating medications not
pecified (dietary supplements or multivitamins containing a
aily dose of niacin 250 mg were allowed); 2) history of
tatin intolerance; 3) history of chronic viral hepatitis
including presence of hepatitis B surface antigen or hepa-
itis C antibody) or other chronic hepatic disorders, alanine
minotransferase or aspartate aminotransferase 1.5 times
he upper limit of normal, or alkaline phosphatase or total
ilirubin 1.5 times the upper limit of normal of laboratory
eference range at screening; 4) renal impairment with
reatinine clearance 50 ml/min; 5) history of myopathy or
nflammatory muscle disease, or elevated total serum crea-
ine kinase (3 times upper limit of normal) at screening visit;
) Doppler assessment of 40% stenosis or carotid occlu-
ion during screening assessment; 7) history of clinically
ignificant atopy (e.g., anaphylaxis, skin rash to medication
r topical therapies, hypersensitivity to iodinated contrast
edia, allergies to food such as shellfish, bronchial asthma)
nd allergies to dextran and iron salts; 8) clinical contrain-
ications to MRI including but not limited to intracranial
neurysm clips (except Sugita) with an appropriate operative
onformation, history of intraorbital metal fragments, pace-
akers and non-MRI compatible heart valves, inner ear
mplants, or history of claustrophobia in MRI; 9) planned
arotid surgery or endovascular intervention within 10
eeks of the study period; 10) serum triglycerides 400
g/dl (4.52 mmol/l) at screening; 11) untreated or uncon-
rolled hypothyroidism or thyrotoxicosis; 12) patients with
oorly controlled diabetes mellitus with hemoglobin A1c
8.5%; 13) patients with poorly controlled hypertensionsystolic blood pressure 160 mm Hg and/or diastolic clood pressure 100 mm Hg); 14) history of malignancy
ithin the past 2 years, other than nonmelanoma skin
ancer; 15) evidence of recent (4 weeks) severe infection
e.g., pneumonia, cellulitis); 16) current life-threatening
ondition other than vascular disease (e.g., very severe
hronic airways disease, human immunodeficiency virus
ositive, life-threatening arrhythmias) that may prevent
ubject from completing the study; 17) history of myocardial
nfarction or cerebrovascular accident within the previous 2
eeks of screening; 18) concomitant use of potent CYP450
A4 inhibitors (e.g., clarithromycin, grapefruit juice [240
l daily], itraconazole, ketoconazole); 19) chronic use of
onsteroidal anti-inflammatory drugs and oral steroids ther-
py (“cardiovascular” doses of aspirin up to 325 mg daily
ere allowed); 20) chronic use of immunosuppressants
cyclosporine, methotrexate, and so forth); 21) use of an
nvestigational drug within 30 days or 5 half-lives (which-
ver is the longer) preceding the first dose of study medi-
ation; 22) inability to give informed consent; 23) prior
psilateral carotid endarterectomy or neck irradiation; and
4) alcohol or drug abuse within the past 6 months.
The conduct of the MRI studies did not cause a delay in
urgical intervention of any of the enrolled subjects because
lanned carotid surgery or endovascular intervention earlier
han 10 weeks within the study period was an exclusion
riterion. Patients who withdrew from the study for safety
easons or otherwise were replaced with new patients with a
orresponding treatment unit number so that the final
umber in each group would be balanced (n  20).
igh-resolution multisequence MRI. Multicontrast im-
ging of both the left and right internal carotid artery was
cquired at 1.5-T before USPIO infusion and 36 h after
nfusion, using a whole-body MRI system (Signa HDx, GE
iagnostic Imaging, Waukesha, Wisconsin) and a custom-
esigned 4-channel phased-array neck coil (PACC, Mach-
et BV, Elde, the Netherlands) to improve signal-to-noise
atio. Movement artifact was minimized using a dedicated
acuum-based head restraint system (VAC-LOK Cushion,
ncology Systems Limited, Crawley, United Kingdom) to
x the head and neck in a comfortable position and allow
lose apposition of the surface coils.
After an initial coronal localizer sequence, axial 2-
imensional time-of-flight MR angiography was performed
o identify the location of the carotid bifurcation and the
egion of maximal stenosis on each side. Axial images were
cquired through the common carotid artery 12 mm (4
lices) below the carotid bifurcation to a point 12 mm (4
lices) distal to the extent of the stenosis identified on the
ime-of-flight sequence. This method ensured that the
ntire carotid plaque was imaged and also facilitated image
oregistration during repeat imaging.
The following 2-dimensional electrocardiography-
riggered, fat-suppressed fast spin echo pulse sequences
mploying double-inversion recovery blood suppression
ith a voxel size of 0.4  0.4  3mm were used in eachase: T1-weighted (repetition time [TR]/effective echo time
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USPIO-Enhanced MRI Evaluation of Carotid Disease June 2, 2009:2039–50Teeff]/echo train length [ETL]: 1 R-R/7.8 ms/12), short
1inversion recovery (STIR) (TR/TEeff/TI/ETL: 2 R-
/40 ms/150 ms/24), intermediate T2-weighted (TR/
Eeff/ETL: 2 R-R/40 ms/24). T2*-weighted imaging was
erformed using a 2-dimensional multishot spiral acquisi-
ion employing a spectral-spatial excitation pulse (TR/TE:2
-R/5.6 ms). The multishot spiral sequence involved the
cquisition of 22 spiral interleafs each comprising 4,096 data
oints, resulting in an effective in-plane pixel size of 0.42 
.42 mm, 2 signal averages were performed, and a quadruple
nversion recovery (QIR) preparation was utilized to null the
ignal from blood before and after USPIO. Slices were
cquired sequentially with a 3-mm thickness and no inter-
lice gap.
The use of a small field of view means that there are no
ure noise regions with which to adjust the measurements.
he apparent tissue-free regions in the images actually
ontain structured noise, probably due to subtle patient
otion such as swallowing. Because we are using spiral
maging sequences, these artifacts are diffusely spread
round the image rather than being coherent ghosting
rtifacts as would be expected in Cartesian acquisitions. The
sual method of obtaining noise estimates is to take a region
ell away from any tissue to ensure that ghosting artifacts
o not contribute to the measurement. The images in the
gures are windowed such that these artifacts are not
pparent, but that does not mean that the tissue-free regions
rovide valid estimates of background noise.
RI contrast medium. The USPIO compound, Sinerem,
as supplied as a dry powder and initially made up to a
olume of 15 ml with normal saline. The contrast medium
as further diluted in 100 ml of normal saline and given as
slow infusion through an in-dwelling large-bore intrave-
ous cannula over 30 min. The dose used was 2.6 mg/kg.
he physiochemical properties and safety data for this
ontrast agent have been published previously (15). Docu-
ented contrast reactions, albeit rare, include headache,
ausea, vomiting, backache, and hypersensitivity reactions.
2*-weighted quantitative image analysis. All MRI scans
ere analyzed by 2 experienced independent readers
T.Y.T. and S.P.S.H.). The readers were blind to the
atients’ demographic data and statin dose. The sequence
rder of images on the pre-infusion images was maintained
n each set of post-infusion images, but the latter was
iewed in a random order.
Before and after USPIO, MRI scans were manually
oregistered according to plaque morphology and distance
rom the carotid bifurcation at the time of imaging. After
his, images were manually segmented into quadrants, using
re-defined rules, and therefore less susceptible to interob-
erver error, excluding the luminal blood pool (CMR Tools,
ondon, United Kingdom). A horizontal line was con-
tructed across each image and through the lumen center.
ikewise, a perpendicular line was constructed ensuring that
he “cross hairs” were centered through the lumen. These
uadrants were defined as regions of interest (ROIs), and wean signal before and after USPIO infusion was reported
ithin the CMR Tools software. For each patient, only the
lices containing plaque were analyzed.
Because the neck coil was always in a slightly different
osition between imaging sessions, there was not only
patial but also temporal variation to consider. Hence, signal
ntensities in each quadrant were normalized to the adjacent
ternocleidomastoid muscle before and after USPIO, which
oes not take up Sinerem in any appreciable amount. We
ave attempted to address the issue of coil positioning
ariability by normalizing to the adjacent muscle. Although
here is still a coil inhomogeneity effect, we consider that the
ariation across the diameter of the vessel is not a major
nfluence. Signal intensity change (SI) was then calculated
s the difference (after minus before) in these normalized
uantities. Note that the greater the USPIO concentration
i.e., the greater the macrophage activity), the more negative
he resultant value for SI. It follows that a reduction over
ime in macrophage activity will reduce the post-USPIO
oncentration, and result in a positive change in SI with
ime.
ssessment of cerebral emboli. The Embo-Dop transcra-
ial Doppler (TCD) system (Compumedics Germany
mbH, Singen, Germany) was used (version 2.1, Multi
-Laboratory, Compumedics Germany GmbH). This in-
onates simultaneously at 2.0 and 2.5 MHz, and the
tandard system settings designed to optimize emboli signal
ES) detection as recommended in the Consensus criteria
16) were adhered to. Mean depth was 51.1 mm (SD 4.6).
sample volume of 5 mm3 was routinely employed,
lthough in a few cases, this had to be increased to obtain an
dequate signal. Power was 64 to 100 mW. Bilateral
ecordings were performed for 1 h, although if there were
roblems with insonation, preference was given to the
psilateral middle cerebral artery. The transducers were held
n place by a proprietary headpiece supplied with the system.
he Embo-Dop system uses an event detector system using
previously published algorithm (17) to identify potential
andidate events. No distinction was made between whether
he system categorizes ES into solid or gaseous emboli, as it
as likely that all emboli were solid in nature. The spectra
rom all saved ES were recorded onto the hard drive of the
omputer, and all signals were later reviewed offline in
onsensus by 2 experienced observers in ES detection who
ere blinded to the patients’ demographic and lipid profiles.
hese ES were used for further statistical analysis.
tatistical methods. SAMPLE SIZE CALCULATION. A sample
ize of 40 patients randomly allocated 1:1 to high (80 mg) or
ow (10 mg) doses of atorvastatin was expected to provide
0% power overall to detect a difference (with 5% type-1
rror) between the groups in USPIO-enhanced MRI signal
hange at 12 weeks. Assumptions used in this calculation
ere based on the results of a study comparing a group of
ymptomatic to a group of asymptomatic patients (18) that
stimated the difference between these groups to be 0.097,
ith a between-subject standard deviation of 0.093.
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June 2, 2009:2039–50 USPIO-Enhanced MRI Evaluation of Carotid DiseaseNBLINDING. The trial database was transferred from the
rial center to the sponsor once all end points had been
nalyzed. Unblinding of the treatment assignment occurred
nly after this had happened to avoid bias, and permitted
ndependent confirmation of the analyses.
For continuous variables with a normal distribution, the
ean and SD were reported. For log-normally distributed
ariables (e.g., laboratory parameters), the geometric mean
nd coefficient of variation (%CV) were calculated. For
ount data, the median and range were reported. Baseline
alance was not tested statistically. Interobserver and in-
raobserver agreement for reproducibility and repeatability,
espectively, were determined for quadrant analysis for
SPIO signal change using the Bland-Altman method.
Statistical modeling for estimation and hypothesis testing
as carried out as described in the following text. All
eported p values were 2-sided and not adjusted for multiple
esting. A value of p  0.05 was considered to indicate
tatistical significance.
USPIO-enhanced MRI signal change (SI) was analyzed
sing a repeated-measures mixed model with change from
aseline in SI as the outcome variable. Group (low
ose/high dose), visit (week 6/week 12) and baseline signal
hange were fitted as fixed effects and patient as a random
ffect. Estimates of mean signal change within each group
ere calculated with appropriate 95% confidence interval
CI), adjusting for the correlation between measurements
ade on the same subject. Note that a significant change in
group and a nonsignificant change in another group do
ot necessarily imply that the groups changed differently.
o address this directly, an estimate of the difference
etween groups with an appropriate 95% CI was also
alculated, together with a p value testing the hypothesis of
o difference between groups. Other end points were
nalyzed using similar models, but assuming a Poisson
ather than a normal distribution for count data. Model
ssumptions regarding homogeneity of variance were veri-
ed by inspection of residual plots. Distributional assump-
ions regarding normality were verified by assessment of
ormal probability plots.
esults
atient population. Recruitment started in July 2006, and
he last subject visit was in August 2007. Sixty-four patients
ere screened, and 47 patients were enrolled into the study.
even patients did not complete the study because of an
dverse event (n  2; both patients were in the high-dose
roup and had deranged liver function tests during the study
hat were outside the limits of acceptability from the
rotocol), withdrawn consent (n  1), or other reasons not
ssociated with this specific study (n  4). All patients
emained asymptomatic during the study, although 1 pa-
ient on the low-dose statin regimen had a completed
psilateral hemispherical stroke 3 weeks after finishing the Vrial. All 40 patients completing the study had, by definition
f trial design, matched baseline and 6- and 12-week
SPIO-enhanced MRI studies for identification of the
essel boundaries and compositional analysis. These 40
atients comprised the analysis population (Online Figure).
o enrolled patient had a high-grade symptomatic stenosis,
s they would have been operated upon within 2 weeks of
resentation according to local protocol.
Patient demographics are shown in Table 1. A compar-
son of laboratory measures, image analysis, and TCD end
oints at baseline is presented in Table 2. In general,
ifferences between the high- and low-dose groups were
mall. The 6-year difference in age between the groups was
ot considered clinically relevant.
maging analysis. Patients had between 3 and 8 MRI
lices, providing cross-sectional images of the carotid
laque. This resulted in a mean of 4.6 slices per high-dose
atient (range 3 to 6), and 4.75 slices per low-dose patient
range 3 to 8). Two patients (1 high dose, 1 low dose) had
ilateral carotid disease. Both sides from these patients were
ncluded for analysis.
greement. Interobserver agreement was high for USPIO
ignal change calculations. The intraclass correlation coef-
cient (1-way random effects) was 0.90. The 95% limits of
greement were 0.146 to 0.168. This was based on 10
atients, 24 paired patient visits, 118 slices, and 906
atched quadrants. There was some evidence that for
uadrants with a relatively large signal, 1 reader derived a
ess extreme value than the other, although the number of
uadrants affected by this was 3%. Repeatability was also
ased on 10 patients, 58 slices, and 232 matched serial
uadrants. The intraclass correlation coefficient was 0.85
etween 0 and 6 weeks and 0.81 between 6 and 12 weeks on
he pre-USPIO imaging scan.
rimary analyses. Results of the statistical analysis of the
hange from baseline in image analysis, microemboli counts,
atient Demographics
Table 1 Patient Demographics
Combined
Low-Dose
Atorvastatin
High-Dose
Atorvastatin
n 40 20 20
Age, yrs 67.6 7.7 64.7 7.6 70.8 6.7
Male 36 (90) 18 (90) 18 (90)
Percent luminal stenosis 61.7 11.4 64.2 12.1 59.2 10.3
Body mass index, kg/m2 27.2 4.3 26.5 4.0 27.6 4.7
Hypertension 37 (93) 18 (90) 19 (95)
Diabetes mellitus 4 (10) 2 (10) 2 (10)
Peripheral vascular operations 7 (18) 4 (20) 3 (15)
Prior myocardial infarction 7 (18) 5 (25) 2 (10)
Current or former smoker 30 (75) 14 (70) 16 (80)
Family history of heart disease 9 (23) 4 (20) 5 (25)
Hypercholesterolemia 11 (28) 6 (30) 5 (25)
Statin use before enrollment 39 (98) 20 (100) 19 (95)
Antiplatelet agent 38 (95) 19 (95) 19 (95)alues are n (%) or mean  SD.
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USPIO-Enhanced MRI Evaluation of Carotid Disease June 2, 2009:2039–50aboratory measures, and biomarkers are presented in Table 3.
ignificant differences were seen between groups at 12
eeks for SI, microemboli count, LDL-C, total choles-
erol, and plasma Lp-PLA2 activity. Atorvastatin concen-
rations in the 2 groups are also presented. The mean
oncentration was approximately 5-fold higher in the high-
ose group, though the range of concentrations was very
arge.
Examples of the imaging obtained from a low- and high-
ose patient are shown in Figures 1 and 2, respectively.
igure 3 is another example of a high-dose patient at baseline
nd at 12-week imaging. It also depicts the quadrant analysis
pproach used in the image analysis. Figures 4 and 5 show the
hange in signal intensities and microemboli count, respec-
ively, at 6 and 12 weeks.
ost hoc analysis. Although the following was not iden-
ified as a primary or secondary end point before trial
nitiation, we evaluated our results for possible associations
etween changes in serum cholesterol levels and changes in
SPIO-enhanced MRI-defined inflammation and other
easurements. We observed a number of moderate corre-
ations (Spearman |r|  0.4 to 0.6), including between
elative changes in SI and LDL-C (Spearman r  0.48,
 0.0036), between changes in SI and change in
icroemboli count (Spearman r0.58, p 0.0004), and
etween changes in LDL-C and change in microemboli
aseline Characteristics
Table 2 Baseline Characteristics
Low-Dose
Atorvastatin
High-Dose
Atorvastatin
SI, mean  SD 0.075 0.126 0.151 0.128
Microemboli count,
median (range)*
2 (07) 3 (010)
LDL-C, mmol/l,
geometric mean (%CV)†
2.27 (30%) 2.51 (38%)
HDL-C, mmol/l,
geometric mean (%CV)†
1.23 (29%) 1.30 (34%)
Total cholesterol, mmol/l,
geometric mean (%CV)†
4.07 (21%) 4.51 (26%)
Triglycerides, mmol/l,
geometric mean (%CV)†
1.11 (51%) 1.22 (61%)
Highly specific C-reactive
protein, mg/l,
geometric mean (%CV)
1.65 (130%) 1.53 (162%)
Plasma MPO, pmol/l,
geometric mean (%CV)
490 (50%) 425 (54%)
Plasma Lp-PLA2 activity, mol/min/l,
geometric mean (%CV)
152 (20%) 147 (15%)
Atorvastatin equivalent dose, mg,
mean  SD
12.8 5.7 13.6 7.1
Atorvastatin concentration, ng/ml,
at 6 weeks, geometric mean (range)
2.0 (0.18.6) 9.5 (1.2195.4)
Atorvastatin concentration, ng/ml,
at 12 weeks, geometric mean (range)
2.0 (0.86.8) 11.9 (1.879.4)
3 subjects in each group did not have evaluable transcranial Doppler data. †1 subject in each
roup did not have clinical chemistry measured.
HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol; Lp-PLA2
ipoprotein-associated phospholipase A2; MPO  myeloperoxidase; %CV  coefficient of variation;
SI  change in signal intensity.ount (Spearman r  0.55, p  0.0018).
(hange in Magnetic Resonance Imaging Signalnte sity, icroemboli C unt, and Lip d Profiles
Table 3 Change in Magnetic Resonance Imaging SignalIntensity, Microemboli Count, and Lipid Profiles
Week
Low-Dose
Atorvastatin
High-Dose
Atorvastatin Difference
SI (change) 6 0.048 0.131 0.084
(0.018 to 0.114) (0.065 to 0.198) (0.012 to 0.179)
0.1502 0.0003 0.0849
12 0.038 0.203 0.240
(0.111 to 0.036) (0.129 to 0.276) (0.134 to 0.347)
0.3039 0.0001 0.0001
Microemboli
count
6 38% 71% 79%
(10% to 113%) (83% to49%) (90% to57%)
0.1389 0.0001 0.0001
12 51% 91% 94%
(1% to 131%) (97% to78%) (98% to84%)
0.0554 0.0001 0.0001
LDL-C 6 5% 22% 26%
(5% to 15%) (30% to15%) (35% to15%)
0.3336 0.0001 0.0001
12 1% 29% 28%
(13% to 11%) (37% to19%) (39% to14%)
0.8140 0.0001 0.0006
HDL-C 6 0% 1% 1%
(10% to 11%) (11% to 10%) (15% to 15%)
0.9757 0.8393 0.9014
12 2% 3% 1%
(7% to 3%) (9% to 3%) (8% to 8%)
0.4024 0.3052 0.8527
Total cholesterol 6 2% 15% 16%
(5% to 10%) (21% to8%) (25% to7%)
0.5897 0.0001 0.0013
12 3.3% 15.4% 12.6%
(11% to 5%) (22% to8%) (23% to1%)
0.4237 0.0003 0.0294
Triglycerides 6 10% 18% 8%
(23% to 6%) (29% to2%) (27% to 16%)
0.2017 0.0251 0.4686
12 8% 5% 4%
(26% to 13%) (23% to 17%) (23% to 39.%)
0.4025 0.6220 0.8062
High-sensitivity
C-reactive
protein
6 23% 20% 35%
(15% to 78%) (44% to 16%) (61% to 10%)
0.2544 0.2349 0.1030
12 15% 20% 5%
(45% to 30%) (43% to 22%) (48% to 73%)
0.4395 0.2979 0.8584
PlasmaMPO 6 1% 9% 10%
(12% to 16%) (21% to 5%) (26% to 9%)
0.8473 0.1809 0.2804
12 4% 14% 11%
(17% to 12%) (26% to0%) (28% to 10%)
0.6251 0.0443 0.2771
Plasma Lp-PLA2
activity
6 1% 17% 16%
(6% to 5%) (21% to12%) (23% to10%)
0.7883 0.0001 0.0001
12 0% 16% 16%
(5% to 6%) (20% to11%) (23% to9%)
0.9074 0.0001 0.0001
alues are presented as change or percentage change with the associated 95% confidence interval
in parentheses) and p values in italics; bold values highlight statistically significant values.
Abbreviations as in Table 2.
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acrophage infiltration has been identified as one of the
eading risk factors for plaque rupture. USPIO-enhanced
RI has been shown to be potentially able to identify
acrophage-rich plaques in vivo in human carotid arteries
4), and once a vulnerable plaque is found, sequential
ollow-up of this is important to ensure that effective
edical or surgical therapy is instituted to prevent cerebral
vents. Monitoring lipid therapy alone is insufficient for
etermining the therapeutic effect of drugs because although
tatins can reduce plasma cholesterol, they do not always
ecrease macrophage infiltration (19). To study change in
laque morphology after a therapeutic intervention, an
maging method is required that can provide accurate
ssessment of plaque tissue components and activity. Several
maging methods including X-ray angiography, ultrasonog-
aphy, and computed tomography have been used to study
he arterial wall and assess atherothrombosis, but none of
hese modalities can adequately characterize plaque macro-
hage infiltration. Recent developments in MRI have made
t possible to robustly identify and measure plaque tissue
omposition in vivo (20,21).
The findings presented herein represent the first prospec-
Figure 1 Example of a Low-Dose Patient
T2*-weighted imaging at the carotid bifurcation, before (1) and after (2) ultrasmal
and (C) 12 weeks. Plaque demonstrating USPIO uptake can clearly be seen in the
very similar at all 3 time points. No USPIO uptake is seen in the pre-USPIO imagin
important aspect if repeated infusions are to be used for multiple time point imag
intervention.ive molecular MRI study on the in vivo effects of statin Lherapy on carotid plaque inflammation. We found a
ignificant reduction from baseline in USPIO-enhanced
RI-defined plaque inflammation in the high-dose ator-
astatin group at both 6 and 12 weeks. No difference was
bserved with the low-dose regimen. At 12 weeks, there was
significant mean signal difference between the 2 groups.
torvastatin-induced LDL-C lowering was moderately
orrelated with both attenuation of plaque inflammation
nd a clinical correlate—a reduction in microemboli count
n TCD. These findings provide in vivo evidence that
igh-dose statin therapy might have a beneficial effect on
laque stability.
High-resolution MRI has also previously been used for
laque burden regression assessment. In the case of statin-
nduced atherosclerotic plaque modulation, these effects
ave been consistently reported only after at least 1 year of
herapy: Corti et al. (22) showed a decrease in carotid and
ortic plaque size and increase in luminal area after 2 years
f simvastatin monotherapy. In a follow-up study, they
xtended their observations to note that aggressive dosing of
imvastatin compared with conventional therapy did not
esult in a greater change in plaque size, and concluded that
hanges in vessel wall parameters are more related to the
paramagnetic iron oxide (USPIO) infusion at the 3 time points of (A) 0, (B) 6,
upper quadrant in all cases (yellow arrowheads). Pre-USPIO imaging remains
or 12 weeks, indicating that the Sinerem has been cycled out of the plaque, an
d assessing progression of USPIO-defined inflammation in response to a drugl super
right
g at 6
ing anDL-C reduction rather than to the dose of statin given
(
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statin Treatment on Carotid Artery Atheroma: a Magnetic
esonance Imaging Observation) trial found a significant
eduction in the proportion of carotid plaque composed of
ipid and a significant increase in fibrous tissue over the
ourse of 2 years treatment with rosuvastatin (24), but again,
id not observe a measurable difference as a consequence
f using a higher dose of rosuvastatin. Lima et al. (25)
emonstrated statin-induced plaque regression in the
horacic aorta 6 months after the onset of MRI-
onitored statin therapy, although the temporal differ-
nce in the onset of documented plaque modulation
ould be explained by the difference in vascular bed under
crutiny.
We measured an effect after only 6 weeks with high-dose
torvastatin, and rather than targeting plaque area/volume
hanges, which has been shown to take months to years to
etect a difference, we have looked at change in macrophage
nfiltration and inflammation. Our results are in keeping
ith previous data that intensive treatment with atorvastatin
ecreases the inflammatory activity of carotid plaques at 1
onth (26). Furthermore, Crisby et al. (27) demonstrated
Figure 2 Example of a High-Dose Patient
T2*-weighted imaging of a left common carotid artery before and after ultrasmall s
(C and D) 6, and (E and F) 12 weeks. (B) USPIO uptake can clearly be seen in th
similar at all 3 time points with Sinerem having been cycled out of the plaque befo
arrowhead). This signifies that there is a predominant T1 effect, indicating minima
residual USPIO signal is also seen in the pre-USPIO imaging at 12 weeks, and (F)
arrowheads).hat patients after 12 weeks of statin treatment had less lipid snd oxidized LDL-C and fewer macrophages and T cells in
heir endarterectomized carotid samples compared with
atients without statin therapy. In the MIRACL (Myocar-
ial Ischemia Reduction With Aggressive Cholesterol Low-
ring) trial (28) and the PROVE-IT (Pravastatin or Ator-
astatin Evaluation and Infection Therapy) trial (29),
ignificant benefits, namely, decreased incidence of unstable
ngina, occurred within the first month of treatment.
ence, our study may support the hypothesis that damp-
ning of plaque inflammation rather than morphological
egression plays a role in the mechanism underlying the
arly beneficial effects of statins seen in clinical practice. The
act that we did not observe a measurable signal difference
ith the low-dose group may have been because most of the
atients were statin-primed before enrollment, and there-
ore did not show a strong serological response to low-dose
torvastatin. Many of the patients in the other trials de-
cribed were either statin naïve or had their lipid-lowering
rugs discontinued during the lead-in period of the study
nd were therefore more likely to be more sensitive to
ow-dose statin administration than were participants in the
urrent trial. Placebo was not considered ethical in our
ramagnetic iron oxide (USPIO) infusion at the 3 time points of (A and B) 0,
ue at baseline (yellow arrowhead). (C and E) Pre-USPIO imaging remains very
maging (red arrowhead). (D) The plaque begins to enhance at 6 weeks (blue
O uptake and a lack of activated macrophages (minimal inflammation). (E) No
l enhancement post-USPIO can be seen with no evidence of signal voids (blueuperpa
e plaq
re rei
l USPI
signatudy.
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June 2, 2009:2039–50 USPIO-Enhanced MRI Evaluation of Carotid DiseaseThe effects of high- or low-dose atorvastatin on the
ystemic inflammatory markers, except for Lp-PLA2, were
ot significant, which may have been due to the small
ample size used. We were also surprised to find that
eduction in plaque inflammation was not correlated with
he increase in high-density lipoprotein cholesterol
HDL-C) in the high-dose group. Previous studies have
ound that increasing HDL-C with statin therapy may have
positive impact not only on the morphology (24), namely,
eduction of lipid core, but also on attenuation of plaque
nflammation (30). However, it is also possible that pleio-
ropic effects other than an HDL-C–dependent mechanism
ediate the anti-inflammatory effect of atorvastatin.
Methods must be reproducible as well as accurate if they
re to be useful in clinical practice. We have shown that
nterobserver reproducibility of USPIO signal change on
igh-resolution MRI as a marker of plaque inflammation
as high. That stems from the method of segmenting the
laque into quadrants using pre-defined objective rules, as
Figure 3 A High-Dose Patient, Further Example and Quadrant A
T2*-weighted imaging of a right common carotid artery before and after ultrasmall
(C and D) 12 weeks. (B) USPIO uptake can clearly be seen in the plaque at base
sion at 12 weeks (red arrowheads). (D) The plaque enhances at 12 weeks (blue
defined inflammation. Plaque segmentation was performed using a combination of
divide the vessel into quadrants. Signal from artifact, extravascular structures, andescribed in the methodology. In fact, in the sample of alaques investigated in this study, agreement was better
han for the different measurements of luminal stenosis used
nd for identification and quantification of carotid athero-
clerotic plaque components on MRI (31). An intraclass
orrelation coefficient of 0.8 between signal data for
atched quadrant data before USPIO at 0, 6, and 12 weeks
uggests that the technique is repeatable. No USPIO uptake
as seen in the pre-imaging at either 6 or 12 weeks.
herefore, it is likely that USPIO particles have been cycled
ut of the plaque. This finding clearly has implications for
uture prospective sequential studies to assess inflammatory
ctivity because evidence of residual USPIO signal at 6 or 12
eeks before infusion would limit the usefulness of the
echnique.
Atorvastatin therapy itself is unlikely to affect USPIO-
ased macrophage detection by MRI, a prerequisite for the
se of this contrast material to examine lesion macrophage
urden during lipid-lowering therapy. A recent study
howed that nontoxic concentrations of atorvastatin did not
is Approach
aramagnetic iron oxide (USPIO) infusion at the 2 time points of (A and B) 0 and
ellow arrowheads). (C) Sinerem has been cycled out of the plaque before reinfu-
eads), indicating that the high-dose statin treatment has damped the USPIO-
ontrast sequences. The cross hairs centered through the middle of the lumen
uminal blood pool (green asterisks) are excluded from the analysis.nalys
superp
line (y
arrowh
multic
the lffect the amount of USPIO taken up by macrophages in
v
o
r
S
l
s
p
h
e
e
l
U
a
d
p
b
i
t
s
u
m
(
d
w
a
d
t
i
i
m
a
p
T
c
a
s
R
w
m
f
0
p
a
b
t
i
i
s
w
t
q
c
q
n
a
o
s
a
a
f
a
u
2
d
i
2048 Tang et al. JACC Vol. 53, No. 22, 2009
USPIO-Enhanced MRI Evaluation of Carotid Disease June 2, 2009:2039–50itro (32). Furthermore, the intracellular distribution of iron
xide nanoparticles and the resulting MRI signal intensities
emained unchanged by statin treatment.
tudy limitations. Our study should be interpreted in
ight of certain limitations. The sample size is relatively
mall but was adequately powered for the primary end
oint. Although this and other earlier studies (4,33,34)
ave demonstrated the technical feasibility of USPIO-
nhanced MRI, the diagnostic accuracy and potential
ffect on clinical management are yet to be defined in
arger-scale studies. Moreover, the disadvantages with
SPIO-MRI include the fact that at least 2 MRI studies
re required before and after infusion of contrast me-
ium. In times of low budget and a demand for fast
atient throughput, a test with immediate results would
e desirable. Recently, ultrashort echo time subtraction
maging has shown promise, which may remove the need
o perform the pre-infusion MRI study (35).
The relatively modest mean percentage reduction in a
ignal loss can sometimes only be appreciated with the
se of dedicated quantitative algorithms and can be
asked, for instance, in plaques with heavy calcification
4). New image-acquisition methods, for example, gra-
ient echo acquisition for superparamagnetic particles
ith positive contrast, that allow USPIO to be detected
s a strong positive contrast enhancement have been
eveloped in vitro with promising results but are yet
o be implemented in human carotid atheroma imag-
ng (36).
Although T2*-weighted imaging does allow the visual-
zation of the effect of USPIO particles, there has been
uch debate in the literature as how best to quantify this
nd whether the degree of signal loss is in any way
roportional to the inflammatory load within the plaque.
Figure 4 Signal Change
Change from baseline in signal intensity (SI) is plotted for the 2 treatment
groups, low dose (red solid line) and high dose (blue broken line), at 6 and
12 weeks with 95% confidence intervals.rivedi et al. (37) used manually delineated ROIs andalculated the normalized signal change between before and
fter USPIO images. The signal was normalized to the
ignal in the adjacent sternocleidomastoid muscle and any
OI drawn that showed an actual normalized signal drop
ere taken to indicate USPIO uptake; this showed only a
oderate correlation with macrophages staining positively
or USPIO on Perls staining (Pearson’s product moment
.6). Although useful, this technique has an inherent
roblem of bias and observer error, leading to some question
s to its usefulness in the quantification of inflammatory
urden.
A more recent approach has been to arbitrarily divide
he vessel wall in each slice into quadrants by construct-
ng perpendiculars to the horizontal axis across the
mage. This technique, which has been adopted in this
tudy, has the advantage that data points come from the
hole vessel and every section that has plaque, rather
han the rather biased population of ROI. Thus, a
uadrant showing signal loss, once normalized to adja-
ent muscle, is taken to mean USPIO uptake in that
uadrant.
While eliminating operator bias, this technique has a
umber of problems associated with it. First, small focal
reas of signal loss may be lost in a quadrant when regions
f signal enhancement are found around it, limiting the
patial resolution of the analysis. Second, any statistical
nalysis needs to consider the quadrants as populations
nd compares 1 population with another (e.g., quadrants
rom symptomatic patients against quadrants from
symptomatic patients). For parametric statistics to be
seful, a number of assumptions are made. A simple
-tailed t test assumes that the quadrants are normally
istributed and that each quadrant represents a totally
ndependent observation. However, the assumption that
Figure 5 Transcranial Doppler Data
Relative change from baseline in microemboli count is plotted for the 2 treat-
ment groups, low dose (red solid line) and high dose (blue broken line), at 6
and 12 weeks with 95% confidence intervals.
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ervation is obviously overly simplistic.
One quadrant is likely to depend on another to some
xtent, not only within the slice but also between the slices.
ata will therefore be clustered, and simple parametric
tatistics will therefore falter because the number of degrees
f freedom for a simple t test will be related to the number
f quadrants rather than to the number of patients, and
herefore the overall test statistic will be calculated to be
rtificially high. Thus, any p value will be artificially low. In
n attempt to tackle these problems, a complex repeated-
easures mixed model was used to model true variances in
uadrant data.
Another study limitation is that, by design, we in-
luded patients who were not symptomatic from their
arotid disease, and it might therefore be argued that our
opulation did not cover the whole spectrum of disease
everity, bringing into question the generalizability of our
esults. However, patients included in this study are those
or whom the benefit of carotid endarterectomy is still
ontroversial and for whom much is to be expected from
oninvasive imaging techniques and intervention.
onclusions
here is an increasing desire to formulate surrogate end
oints for clinical trials, with biomarkers and imaging
eing possible candidates for assessing underlying dis-
ase. Such surrogates might allow more timely assess-
ent of the efficacy or futility of a proposed intervention.
he problem that pharmaceutical companies and regula-
ory authorities face is that, to demonstrate a clinical
enefit using accepted outcome measures such as stroke
r death, clinical studies need to recruit thousands of
atients and rely on them undergoing such an event (38).
maging of arterial disease that can detect changes in vessel
tructure or function could hasten the development process on
maller number of patients and allow intervention at an earlier
tage in the disease process. There is increasing evidence from
he coronary literature that imaging can be used to monitor the
ffects of interventions such as statin therapy. Measures of
arotid intima-media thickening using ultrasonography have
een validated and have been approved by the FDA to be used
n clinical trials. The literature concerning the assessment of
nterventions using MRI is somewhat less mature.
This is, to our knowledge, the first study of a targeted
RI contrast agent used in humans to assess therapeutic
esponse in an interventional drug trial. Simultaneously, it
acilitated the enrichment of a trial population so that only
ubjects with plaque inflammation were selected for enroll-
ent into the study. Aggressive lipid-lowering therapy over
12-week period is associated with a significant reduction
n USPIO-defined inflammation. As validation continues,
SPIO-enhanced MRI methodology may be a useful im-
ging biomarker for the screening and assessment of ther-
peutic response to anti-inflammatory interventions in pa-
1ients with carotid atherosclerotic lesions. Serial studies
nvolving a larger population of patients are needed to
etermine whether attenuation of plaque inflammation as
efined by USPIO-enhanced MRI can be correlated with a
educed risk of developing clinical symptoms.
eprint requests and correspondence: Dr. Jonathan H. Gillard,
ox 219, Level 5, University Department of Radiology, Cam-
ridge University Hospitals NHS Foundation Trust, Hills Road,
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